U.S. Markets closed

4 Healthcare Stocks Making Moves On Wednesday (1/23/19)

CORAL GABLES, FL / ACCESSWIRE / January 23, 2019 / The future of healthcare stocks, and the medical sector industry as a whole, is solely dependent on the ability of medical experts and healthcare professionals to work to provide the best quality of care for patients in the space.

With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As companies in the healthcare industry work to better understand the needs of their patients, the sector, in its entirety, may boast impressive opportunities for investors looking to the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Auris Medical Holding AG (EARS), Neovasc Inc (NVCN), and Rigel Pharmaceuticals Inc (RIGL) are 4 healthcare stocks representing companies invested in the future of global health.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) has enjoyed impressive gains over the last three weeks as the company has taken strides to make key investments in products and acquisitions meant to strengthen their offerings for their massive patient network.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced last week that as part of its international expansion strategy, it has entered into a strategic partnership with China'a 360 Health, a healthcare subsidiary of 360 Security Technology. The parent company, 360 Security Technology, is a leading online service company in China with a market capitalization of over $20 billion USD as of January 16, 2019. As part of the collaboration, Premier and 360 Health will implement an infrastructure whereby Premier will be providing second opinion services by connecting 360 Health's patients in China with doctors in Canada both remotely and in person. Premier will also assist with General Practitioner training virtually and onsite through medical seminars.

In response to the announcement, Dr. Essam Hamza, CEO of Premier, said, ''We are very excited to be working with 360 Health as China continues to adopt a Family Practice primary care model and look forward to helping them establish themselves as a leader in primary care. This partnership represents an excellent opportunity for Premier to tap into the fastest growing telemedicine market globally.''

For More Information On Premier Health Group, Click Here

Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address ailments relating to the central nervous system, today announced highlights of a recent article which was published to demonstrate that betahistine promotes the retrieval of forgotten memories in mice, and the contents of the article may present potential opportunities for the company.

Thomas Meyer, Auris Medical's founder, Chairman, and CEO, said, ''The exciting outcomes from this study add to the growing body of evidence supporting the important role of histamine in the acquisition, storage and retrieval of memory and suggest further potential uses for betahistine. Histamine plays a key role in the regulation of a wide range of behavioral and physiological functions, including appetite, drinking, sleep, wakefulness, learning, attention and memory. Earlier studies with betahistine already showed positive effects on learning and cognitive function.''

For More Information On Auris Medical Holding AG, Click Here

Neovasc Inc (NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies, as well as in the development of minimally invasive devices related to the treatment of refractory angina, today announced that the Journal of the American College of Cardiology; Cardiovascular published a peer-reviewed article on the use of dipyridamole stress perfusion cardiac magnetic resonance performance of its Neovasc treatment for angina.

In a press release regarding the publishing of the journal, Fred Colen, Neovasc's President and Chief Executive Officer, commented, ''The authors of this article point to objective evidence available via stress perfusion CMR, providing insights into the potential impact of the Reducer on the ischemic burden, suggesting a physiological rationale as to how the Reducer reduces a perfusion defect in this patient. Stress perfusion CMR is emerging as the noninvasive gold standard for the assessment of ischemia.

For More Information on Neovasc, Inc., Click Here

Rigel Pharmaceuticals Inc (RIGL) found itself in headlines before the opening bell as the Company today announced that it has entered into an exclusive license and supply agreement with Spain-based Grifols, S.A. to commercialize treatments in all potential indications in Europe and Turkey.

Following the announcement of the agreement, Raul Rodriguez, President and CEO of Rigel, said, ''Grifols has a broad presence in Europe and an established position in the hematology commercial landscape, which supports our goal of bringing fostamatinib to patients in these countries. Our marketing authorization application for fostamatinib in chronic ITP is currently under review by the European Medicines Agency, and we anticipate a decision by the end of 2019."

For More Information On Rigel Pharmaceuticals Inc., Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 -4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/23/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.



SOURCE: Stock Price